ClinicalTrials.gg
RecruitingNCT07109427Updated Aug 19, 2026

Impact of an Electronic Health Record Maintenance Alert on PSA Screening Rates in a 10-Hospital Integrated Health System

An interventional study of Annual PSA Health Maintenance Reminder in Prostate Cancer and Cancer of the Prostate, sponsored by Washington University School of Medicine. Recruiting at 1 site in United States. Open to male participants aged 40 Years to 75 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-08-19.

Sponsored by Washington University School of Medicine · Not applicable, Interventional, and Health services research

How we know

From the registry’s dates

  • Started Aug 2025; still recruiting 1 year 3 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
40,000
Allocation
Not applicable
Ages
40 Years to 75 Years
Sex
Male
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 23 studies in Prostatic Neoplasms by Washington University School of Medicine — 9 open to participants now, 11 under way, none of them phase 3. Prostatic Neoplasms · Washington University School of Medicine.

Planned enrollment
Largest of 20
40,000 · median 35
Started
2025
the only one that year
No phase
12 of 23
4 open now
Primary completion
2031-08
later than 9 of 10 live
Registered
18th of 23
by date

Among the 23 studies in Prostatic Neoplasms by Washington University School of Medicine, this one has the largest planned enrollment of the 20 interventional ones that give a count, is the only one that started in 2025, is one of 12 with no phase, reaches primary completion later than 9 of the 10 other live ones, and was the 18th registered.

Prostatic Neoplasms

7,058 studies on the registry are indexed under Prostatic Neoplasms; 1,582 are open to participants now.

Browse Prostatic Neoplasms studies →

Open to participants now

9 of the 23 studies in Prostatic Neoplasms by Washington University School of Medicine are open now, in 1 country. Recruiting first, the newest first:

3 more — sign in →

By country, each count listing its studies:

All 9 open studies →

Where they have run

Who these studies take

Of the 1,236 Prostatic Neoplasms studies recruiting now, 933 (75%) set no upper age limit and 77 (6%) stop at 75 or younger; 67 take children under 18; 82 take healthy volunteers.

This study: 40 Years to 75 Years · male · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 23 studies in Prostatic Neoplasms by Washington University School of Medicine, or all of them as a file.
02

Study summary

- The investigators propose a clinical trial to evaluate the impact of annual shared decision making for PSA screening, supported by system-level enhancements to promote evidence-based care:

  • Defined referral thresholds within the health maintenance reminder, aligned with clinical risk stratification per NCCN guidelines.
  • Enhanced clinical decision support (CDS) tools to reduce provider variation and ensure guideline-concordant screening and referral practices.
  • The goal is to reduce late-stage presentation without increasing overdiagnosis-ensuring that prostate cancer screening is both accessible and clinically effective.
03

Conditions studied

  • Prostate Cancer
  • Cancer of the Prostate

Browse trials for

Keywords

  • PSA Screening
  • Clinically Significant Prostate Cancer
  • African American men
  • Electronic Health Record
04

Who can participate

Ages eligible
40 Years to 75 Years
Sexes eligible
Male
Accepts healthy volunteers
Yes

Eligibility criteria

Eligibility Criteria:

  • Receive care within the BJC Health System
  • Have had at least one primary care physician appointment in the calendar year of PSA screening (primary care)
  • Be male
  • Not have a history of prostate cancer
  • Meet one of the following risk criteria:

    • High Risk for Prostate Cancer

      • African American, between the ages of 40 and 75 (inclusive), or
      • Family history of prostate, breast, ovarian, and/or pancreatic cancer, or
      • Known familial germline mutation OR
    • Average Risk for Prostate Cancer

      • Between the ages of 50 and 75 (inclusive)
05

Study design

Phase
Not applicable
Primary purpose
Health services research
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
40,000 participants (estimated)

Study arms

  • Experimental
    Annual PSA Health Maintenance Reminder

    An annual health maintenance reminder will be implemented for all men who meet the American Cancer Society guidelines for average- and high-risk eligibility criteria. The goal is to encourage their primary care provider (PCP) to engage in a shared decision-making discussion with the patient about the benefits and risks of prostate cancer screening. This alert will appear in the health maintenance reminder section of the electronic health record (EHR). Although all providers with access to EPIC can view the alert, it is typically the PCPs who review and take action on alerts in the health maintenance reminder section.

    Other: Annual PSA Health Maintenance Reminder

Interventions

  • OtherAnnual PSA Health Maintenance Reminder

    The annual health maintenance reminder does not mandate PSA screening for eligible patients. Instead, it recommends that primary care providers (PCPs) initiate a shared decision-making discussion with their patients. As part of this conversation, patients will be informed of their individual risk factors-including race, family history, and germline mutations-and can then make an informed choice about whether to proceed with PSA screening.

06

What researchers measure

Primary outcomes

  1. Change in PSA screening completion rates in the BJC East Health System

    The overall PSA screening rate will be calculated as the number of PSA screening tests that are ordered by PCPs who will receive the alert and completed by patients within a year of the ordering date, divided by the total number of eligible patients.

    Time frame: Through 5 years

Secondary outcomes

  1. Proportion of men diagnosed with clinically significant prostate cancer (Gleason score ≥ 7)

    Time frame: Through 5 years

  2. Incidence of advanced and metastatic disease at diagnosis of prostate cancer

    Time frame: Through 5 years

  3. Incidence of early-stage prostate cancer

    Time frame: Through 5 years

  4. Stage distribution of prostate cancer diagnoses

    Time frame: Through 5 years

  5. Biopsy rates

    Time frame: Through 5 years

  6. Percent of PSA screening ordered but not completed

    Time frame: Through 5 years

  7. Median PSA at time of diagnosis

    Time frame: Through 5 years

  8. Evaluate the agreement between 3T MRI and biomarker test results

    The 3T MRI and biomarker tests are used to help determine whether a biopsy is necessary. The investigators will categorize the results as positive versus negative and the agreement will be gauged based on Kappa coefficient.

    Time frame: Through 5 years

  9. PSA screening rate by age group

    Age groups will include 40-49, 50-70, and 70-75

    Time frame: Through 5 years

  10. PSA screening rate by race

    Time frame: Through 5 years

  11. PSA screening rate by comorbidity burden

    Time frame: Through 5 years

  12. PSA screening rate by insurance coverage

    Time frame: Through 5 years

  13. PSA screening rate by provider

    Time frame: Through 5 years

07

Study locations

1 of 1 sites recruiting
  • Washington University School of Medicine
    St Louis, Missouri 63110, United States
    Recruiting
    • Lannis Hall, M.D., MPH · Contactlannishall@wustl.edu · 636-916-9947
    • Lannis Hall, M.D., MPH · Principal investigator
    • Saira Khan, Ph.D., MPH · Sub investigator
    • Arnold Bullock, M.D. · Sub investigator
    • Timothy Eberlein, M.D. · Sub investigator
    • Kristina Williams · Sub investigator
    • Cliff Robinson, M.D. · Sub investigator
    • Jingqin (Rosy) Luo, Ph.D. · Sub investigator
    • Christopher Abraham, M.D. · Sub investigator
    • Michael Johnson, M.D. · Sub investigator
08

References and documents

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Aug 2025 (actual). Primary completion is estimated for Aug 2031, 72 months after the start.

Of 1,104 non-industry interventional studies with no phase under Prostatic Neoplasms, half reached primary completion within 43 months of starting (the median), counting those still running; a quarter within 22 and three quarters within 87. This study's planned 72 months is above that.

Counting every sponsor, half of 1,162 studies reached it within 43 months; a quarter within 22 and three quarters within 86.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 31, 2025
First posted
Aug 7, 2025
StartActual
Aug 11, 2025
Primary completionEst.
Aug 31, 2031
CompletionEst.
Aug 31, 2031
Last update
Aug 19, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 19, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07109427
Responsible party
Sponsor
First posted
Aug 7, 2025
Start date
Aug 11, 2025
Primary completion
Aug 31, 2031 (estimated)
Completion
Aug 31, 2031 (estimated)
Last update
Aug 19, 2026

Study contacts

Lannis Hall, M.D., MPH
Contact
lannishall@wustl.edu
636-916-9947
Lannis Hall, M.D., MPH
principal investigator · Washington University School of Medicine

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion